Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mouse gut metagenome

ABSTRACT: Gut bacterial microbiome of mice treated with anti-fungal Amphotericin B Targeted loci

PROVIDER: PRJNA317649 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3420770_1.fastq.gz	Fastqsanger.gz
	SRR3420770_2.fastq.gz	Fastqsanger.gz
	SRR3420780_1.fastq.gz	Fastqsanger.gz
	SRR3420780_2.fastq.gz	Fastqsanger.gz
	SRR3420790_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 82

Similar Datasets

mouse gut metagenome

Project description:mouse gut microbiome Targeted Locus (Loci)

| PRJNA289260 | ENA

Mouse gut microbiome

Project description:Gut microbiome of mice treated with antibiotics and fed different diets Targeted loci

| PRJNA315460 | ENA

Directed Remodeling of the Mouse Gut Microbiome Inhibits the Development of Atherosclerosis [mouse tissue]

Project description:The gut microbiome is a malleable microbial community that can remodel in response to various factors, including diet, and contribute to the development of several chronic diseases, including atherosclerosis. We devised an in vitro screening protocol of the mouse gut microbiome to discover molecules that can selectively modify bacterial growth. This approach was used to identify cyclic D,L-α-peptides that remodeled the Western diet (WD) gut microbiome toward the low-fat-diet microbiome state. Daily oral administration of the peptides in WD-fed LDLr-/- mice reduced plasma total cholesterol levels and atherosclerotic plaques. Depletion of the microbiome with antibiotics abrogated these effects. Peptide treatment reprogrammed the microbiome transcriptome, suppressed the production of pro-inflammatory cytokines (including interleukin-6, tumor necrosis factor-α and interleukin-1β), rebalanced levels of short-chain fatty acids and bile acids, improved gut barrier integrity and increased intestinal T regulatory cells. Directed chemical manipulation provides an additional tool for deciphering the chemical biology of the gut microbiome and might advance microbiome-targeted therapeutics.

2019-12-31 | GSE104914 | GEO

mouse gut metagenome

Project description:Methyl donor microbiome mice Targeted Locus (Loci)

| PRJNA179439 | ENA

mouse gut metagenome

Project description:Uncultured microbiome of mice Targeted Locus (Loci)

| PRJNA194427 | ENA

mouse gut metagenome

Project description:Mouse feces treated with indomethacin Targeted loci environmental

| PRJNA309674 | ENA

Directed Remodeling of the Mouse Gut Microbiome Inhibits the Development of Atherosclerosis [bacteria]

2019-12-31 | GSE104913 | GEO

mouse gut metagenome

Project description:gut microbiome of sublytic mice Targeted Locus (Loci)

| PRJNA294003 | ENA

Comparison of untreated and vancomycin-treated macrophages, with or without Candida albicans infection

Project description:Vancomycin is a widely prescribed antibiotic used in the treatment of Gram-positive bacterial infections. We recently showed that this antibiotic disrupted protective anti-fungal immune responses via microbiome dysbiosis, enhancing susceptibility to invasive candidiasis. Antibiotics are an independent risk factor for developing this life-threatening fungal infection, but whether microbiota-independent mechanisms also drive this association is not clear. Here, we have compared transcriptional responses of mouse bone-marrow derived macrophages at an early time point post-infection (2 hours), comparing back to baseline, using untreated or vancomycin-treated macrophages.

2025-07-01 | GSE269051 | GEO

Effect of amphotericin B on Aspergillus fumigatus

Project description:Amphotericin B (AMB) is the most widely used polyene antifungal drug for the treatment of systemic fungal infections including invasive aspergillosis. We aimed to understand molecular targets of AMB in Aspergillus fumigatus (Afu) by genomic approaches. Keywords: Aspergillus fumigatus treated with amphotericin B for 24 hours

2008-02-14 | GSE10505 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data